(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2012 (19.04.2012)

PCT

(10) International Publication Number
WO 2012/051194 A1

(51) **International Patent Classification**:
C07K 7/64 (2006.01)

(21) **International Application Number**:
PCT/US2011/055791

(22) **International Filing Date**:
11 October 2011 (11.10.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/392,449 12 October 2010 (12.10.2010) US

(71) **Applicant** *(for all designated States except US)*: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **CARLING, William Robert** [GB/GB]; 28 Yeomans Close, Bishop's Stortford Herfordshire CM23 4EU (GB). **FRYDRYCH, Catherine Simone Victorire** [BE/GB]; 5 Pishiobury News, Pishiobury Drive, Sawbridgeworth Hertfordshire (GB). **GARST, Michael E.** [US/US]; 2627 Raqueta Drive, Newport Beach, California 92660 (US). **STERN, Michael E.** [US/US]; 14 Altezza Drive, Mission Viejo, California 92692 (US). **SCHAUMBURG, Christopher S.** [US/US]; 21901 Summer Circle, Huntington Beach, California 92646 (US).

(74) **Agents**: **GERMAN, Joel B.** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/051194 A1

(54) **Title**: CYCLOSPORIN ANALOGS

(57) **Abstract**: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.